Professor, Medicine, Icahn School of Medicine
Oncology
Dr. Randall F. Holcombe, MD
|
|
Give Review
Randall F. Holcombe, MD is an expert in the field of Oncology. He went to medical school at Rutgers New Jersey Medical School. Rutgers New Jersey Medical School has a rank of 76 in research and a 0 in primary care He received awards:"America's Top Doctors", "Top Doctors: New York Metro Area", "New York Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification" and "America's Top Doctors for Cancer". Randall Holcombe has written publications. He has 24 publications published with PubMed. The lastest publication is: 'Predictors of patient satisfaction with inpatient hospital pain management across the United States: A national study.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Predictors of patient satisfaction with inpatient hospital pain management across the United States: A national study.
- Designing a broad-spectrum integrative approach for Cancer prevention and treatment.
- Impact of inpatient radiation on length of stay and health care costs.
- Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid Tumors.
- Cancer Clinical Research: Return on Investment in the Era of Value-Based Purchasing.
- Sweet's Syndrome in a patient with metastatic melanoma after ipilimumab therapy.
- Implementation of Electronic Chemotherapy Ordering: An Opportunity to Improve Evidence-Based Oncology Care.
- Invasive colon Cancer, but not non-invasive adenomas induce a gradient effect of Wnt pathway receptor frizzled 1 (Fz1) expression in the tumor microenvironment.
- Clinical Pathways for Pancreatic Neuroendocrine Tumors.
- Lymphoid enhancer-binding factor 1, a representative of vertebrate-specific Lef1/Tcf1 sub-family, is a Wnt-beta-catenin pathway target gene in human endothelial cells ...
- PR-104 plus sorafenib in patients with advanced hepatocellular Carcinoma.
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder Cancer or cholangiocarcinoma: Southwest Oncology Group study S...
- Mission-focused, proDuctivity-based model for sustainable support of academic hematology/oncology faculty and divisions.
- Limitations of ADAMTS-13 activity level in diagnosing thrombotic Thrombocytopenic purpura in pregnancy.
- WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder Cancer cells.
- Wnt pathway-related gene expression in inflammatory bowel disease.
- Coculture methodologies for the study of Wnt signals.
- In Situ hybridization to evaluate the expression of Wnt and frizzled genes in mammalian tissues.
- Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 c...
- Differential effects of wine consumption on colorectal Cancer outcomes based on family history of the disease.
- Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate Cancer PC-3 cells suppresses tumor growth and...
- Viewpoint: who's watching out for the clinical academician?
- Correction: Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in...
Schools
UmdnjNew Jersey Medical School
BrighamWomens Hospital
Harvard Med School
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors: New York Metro Area
- New York Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
Education
-
Brigham and Women's Hospital -
Rutgers New Jersey Medical School
Hospital
-
Mount Sinai Hospital
Drug Facts
| NPI NUMBER | 1912087073 | |
| NPPES Provider LastName | HOLCOMBE | |
| NPPES Provider FirstName | RANDALL | |
| NPPES Provider ZIPCode | 100296503 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 227.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 5.73 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912087073 |
| Last Name Of The Provider | HOLCOMBE |
| First Name Of The Provider | RANDALL |
| View All |
Similar Doctors
|
Dr. Samuel J. Klempner, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P Fruehauf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Zell, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy E. Byun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Birbal S. Bhaskar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rita Sanghvi Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sherif Rezk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian Kim, MD |
|
|
Dr. Steven A. Armentrout, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rainer Brachmann, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Edgar M. Moran, MD
This Doctor is OpenDoctor Recommended.
|